



ASX ANNOUNCEMENT

16 February 2015

Cynata Engages Contract Research Organisation to Plan Clinical Trial

- *Leading international Contract Research Organisation engaged to fast track plans and logistics for first Cymerus™ stem cell human clinical trial*
- *Initial goal to identify optimal international clinical trial sites*

Melbourne, Australia; 16 February 2015: Australian stem cell and regenerative medicine company, Cynata Therapeutics Ltd (ASX: CYP) has engaged a leading global contract research organisation (CRO) to commence clinical trial planning and logistics development for a Phase 1 clinical study.

On behalf of Cynata, the CRO will undertake and oversee initial planning, including the identification of optimal sites to launch the important Phase I clinical investigation of Cynata's proprietary mesenchymal stem cell (MSC) product.

Cynata's Cymerus™ technology enables large scale production MSCs from a single, one-time donor – a pivotal requirement for pharmaceutical companies moving into stem cell medicine.

Cynata Vice President of Product Development, Dr Kilian Kelly, said the appointment of a CRO was a key step in commercialising this novel platform technology. "Regenerative medicine using mesenchymal stem cells is rapidly gaining momentum globally. The past year has seen Cynata build a solid foundation for its Cymerus™ MSC manufacturing platform and we now look forward to working with our high calibre CRO partner with the formal commencement of logistics planning for a Phase 1 clinical trial."

Further inquiries:

Dr Ross Macdonald
Chief Executive Officer
Tel: 0412 119343
ross.macdonald@cynata.com

Dr Stewart Washer
Executive Chairman
Tel: 0418 288 212
stewart.washer@cynata.com

Emma Power
Monsoon Communications
Tel: 0419 149 525
emmap@monsoon.com.au

Kirin Smith,
PCG Advisory Investor Contact, ,
+ 1 646-863-6519,
ksmith@pcgadvisory.com

Sean Leous,
PCG Advisory Media Contact,
+1 646-863-8998,
sleous@pcgadvisory.com



About Cynata Therapeutics (ASX:CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company developing and commercialising a novel method for producing scalable quantities of mesenchymal stem cells for therapeutic application. The platform technology, Cymerus™, originates from the University of Wisconsin-Madison, a facility that is widely recognised as a world leader in stem cell research. Cynata’s proprietary Cymerus™ technology seeks to address a critical shortcoming in existing production methods of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ achieves this by producing a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA technology provides a source of MSCs that are independent of donor limitations and provide a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. The Cymerus™ technology has great potential to create a new standard globally in stem cell therapeutics, with a novel manufacturing technology and an important competitive position.